Granulocyte-colony stimulating factor (G-CSF or GCSF), also known as colony-stimulating factor 3 (CSF 3), is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream.
Functionally, it is a cytokine and hormone, a type of colony-stimulating factor, and is produced by a number of different tissues. The pharmaceutical analogs of naturally occurring G-CSF are called filgrastim and lenograstim.
G-CSF also stimulates the survival, proliferation, differentiation, and function of neutrophil precursors and mature neutrophils.
The global Recombinant Human Granulocyte Colony-Stimulating market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2022-2027.
The global Recombinant Human Granulocyte Colony-Stimulating market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Recombinant Human Granulocyte Colony-Stimulating market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.
Geographical Analysis:
Based on region, the global Recombinant Human Granulocyte Colony-Stimulating market is segmented into North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America). Research analysts have studied government initiatives, changing the political environment, and social scenarios that are likely to contribute to the growth of the regional markets.
Key Players:
The major players that are operating in the global Recombinant Human Granulocyte Colony-Stimulating market are
Amgen
Qilu Pharmaceutical
Shijiazhuang Pharmaceutical
Kyowa Hakko Kirin
Gensci
Amoytop Biotech
Hangzhou Jiuyuan
Huaxin
Triprime
Sinovac
Zhaoke
Kawin
Segment by Type
Lenograstim (Granocyte)
Filgrastim (Neupogen, Zarzio, Nivestim, Ratiograstim)
Others
Segment by Application
Chemotherapy Induced Neutropenia
Before Blood Donation
Stem Cell Transplants
Others
Functionally, it is a cytokine and hormone, a type of colony-stimulating factor, and is produced by a number of different tissues. The pharmaceutical analogs of naturally occurring G-CSF are called filgrastim and lenograstim.
G-CSF also stimulates the survival, proliferation, differentiation, and function of neutrophil precursors and mature neutrophils.
The global Recombinant Human Granulocyte Colony-Stimulating market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2022-2027.
The global Recombinant Human Granulocyte Colony-Stimulating market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Recombinant Human Granulocyte Colony-Stimulating market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.
Geographical Analysis:
Based on region, the global Recombinant Human Granulocyte Colony-Stimulating market is segmented into North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America). Research analysts have studied government initiatives, changing the political environment, and social scenarios that are likely to contribute to the growth of the regional markets.
Key Players:
The major players that are operating in the global Recombinant Human Granulocyte Colony-Stimulating market are
Amgen
Qilu Pharmaceutical
Shijiazhuang Pharmaceutical
Kyowa Hakko Kirin
Gensci
Amoytop Biotech
Hangzhou Jiuyuan
Huaxin
Triprime
Sinovac
Zhaoke
Kawin
Segment by Type
Lenograstim (Granocyte)
Filgrastim (Neupogen, Zarzio, Nivestim, Ratiograstim)
Others
Segment by Application
Chemotherapy Induced Neutropenia
Before Blood Donation
Stem Cell Transplants
Others
1 Recombinant Human Granulocyte Colony-Stimulating Market Overview
1.1 Recombinant Human Granulocyte Colony-Stimulating Product Scope
1.2 Recombinant Human Granulocyte Colony-Stimulating Segment by Type
1.2.1 Global Recombinant Human Granulocyte Colony-Stimulating Sales by Type (2016 & 2021 & 2027)
1.2.2 Lenograstim (Granocyte)
1.2.3 Filgrastim (Neupogen, Zarzio, Nivestim, Ratiograstim)
1.2.4 Others
1.3 Recombinant Human Granulocyte Colony-Stimulating Segment by Application
1.3.1 Global Recombinant Human Granulocyte Colony-Stimulating Sales Comparison by Application (2016 & 2021 & 2027)
1.3.2 Chemotherapy Induced Neutropenia
1.3.3 Before Blood Donation
1.3.4 Stem Cell Transplants
1.3.5 Others
1.4 Recombinant Human Granulocyte Colony-Stimulating Market Estimates and Forecasts (2016-2027)
1.4.1 Global Recombinant Human Granulocyte Colony-Stimulating Market Size in Value Growth Rate (2016-2027)
1.4.2 Global Recombinant Human Granulocyte Colony-Stimulating Market Size in Volume Growth Rate (2016-2027)
1.4.3 Global Recombinant Human Granulocyte Colony-Stimulating Price Trends (2016-2027)
2 Recombinant Human Granulocyte Colony-Stimulating Estimates and Forecasts by Region
2.1 Global Recombinant Human Granulocyte Colony-Stimulating Market Size by Region: 2016 VS 2021 VS 2027
2.2 Global Recombinant Human Granulocyte Colony-Stimulating Retrospective Market Scenario by Region (2016-2021)
2.2.1 Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Region (2016-2021)
2.2.2 Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Region (2016-2021)
2.3 Global Recombinant Human Granulocyte Colony-Stimulating Market Estimates and Forecasts by Region (2022-2027)
2.3.1 Global Recombinant Human Granulocyte Colony-Stimulating Sales Estimates and Forecasts by Region (2022-2027)
2.3.2 Global Recombinant Human Granulocyte Colony-Stimulating Revenue Forecast by Region (2022-2027)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 North America Recombinant Human Granulocyte Colony-Stimulating Estimates and Projections (2016-2027)
2.4.2 Europe Recombinant Human Granulocyte Colony-Stimulating Estimates and Projections (2016-2027)
2.4.3 China Recombinant Human Granulocyte Colony-Stimulating Estimates and Projections (2016-2027)
2.4.4 Japan Recombinant Human Granulocyte Colony-Stimulating Estimates and Projections (2016-2027)
2.4.5 Southeast Asia Recombinant Human Granulocyte Colony-Stimulating Estimates and Projections (2016-2027)
2.4.6 India Recombinant Human Granulocyte Colony-Stimulating Estimates and Projections (2016-2027)
3 Global Recombinant Human Granulocyte Colony-Stimulating Competition Landscape by Players
3.1 Global Top Recombinant Human Granulocyte Colony-Stimulating Players by Sales (2016-2021)
3.2 Global Top Recombinant Human Granulocyte Colony-Stimulating Players by Revenue (2016-2021)
3.3 Global Recombinant Human Granulocyte Colony-Stimulating Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Recombinant Human Granulocyte Colony-Stimulating as of 2020)
3.4 Global Recombinant Human Granulocyte Colony-Stimulating Average Price by Company (2016-2021)
3.5 Manufacturers Recombinant Human Granulocyte Colony-Stimulating Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Global Recombinant Human Granulocyte Colony-Stimulating Market Size by Type
4.1 Global Recombinant Human Granulocyte Colony-Stimulating Historic Market Review by Type (2016-2021)
4.1.1 Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Type (2016-2021)
4.1.2 Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Type (2016-2021)
4.1.3 Global Recombinant Human Granulocyte Colony-Stimulating Price by Type (2016-2021)
4.2 Global Recombinant Human Granulocyte Colony-Stimulating Market Estimates and Forecasts by Type (2022-2027)
4.2.1 Global Recombinant Human Granulocyte Colony-Stimulating Sales Forecast by Type (2022-2027)
4.2.2 Global Recombinant Human Granulocyte Colony-Stimulating Revenue Forecast by Type (2022-2027)
4.2.3 Global Recombinant Human Granulocyte Colony-Stimulating Price Forecast by Type (2022-2027)
5 Global Recombinant Human Granulocyte Colony-Stimulating Market Size by Application
5.1 Global Recombinant Human Granulocyte Colony-Stimulating Historic Market Review by Application (2016-2021)
5.1.1 Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Application (2016-2021)
5.1.2 Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Application (2016-2021)
5.1.3 Global Recombinant Human Granulocyte Colony-Stimulating Price by Application (2016-2021)
5.2 Global Recombinant Human Granulocyte Colony-Stimulating Market Estimates and Forecasts by Application (2022-2027)
5.2.1 Global Recombinant Human Granulocyte Colony-Stimulating Sales Forecast by Application (2022-2027)
5.2.2 Global Recombinant Human Granulocyte Colony-Stimulating Revenue Forecast by Application (2022-2027)
5.2.3 Global Recombinant Human Granulocyte Colony-Stimulating Price Forecast by Application (2022-2027)
6 North America Recombinant Human Granulocyte Colony-Stimulating Market Facts & Figures
6.1 North America Recombinant Human Granulocyte Colony-Stimulating Sales by Company
6.1.1 North America Recombinant Human Granulocyte Colony-Stimulating Sales by Company (2016-2021)
6.1.2 North America Recombinant Human Granulocyte Colony-Stimulating Revenue by Company (2016-2021)
6.2 North America Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Type
6.2.1 North America Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Type (2016-2021)
6.2.2 North America Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Type (2022-2027)
6.3 North America Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Application
6.3.1 North America Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Application (2016-2021)
6.3.2 North America Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Application (2022-2027)
7 Europe Recombinant Human Granulocyte Colony-Stimulating Market Facts & Figures
7.1 Europe Recombinant Human Granulocyte Colony-Stimulating Sales by Company
7.1.1 Europe Recombinant Human Granulocyte Colony-Stimulating Sales by Company (2016-2021)
7.1.2 Europe Recombinant Human Granulocyte Colony-Stimulating Revenue by Company (2016-2021)
7.2 Europe Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Type
7.2.1 Europe Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Type (2016-2021)
7.2.2 Europe Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Type (2022-2027)
7.3 Europe Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Application
7.3.1 Europe 147 Sales Breakdown by Application (2016-2021)
7.3.2 Europe 147 Sales Breakdown by Application (2022-2027)
8 China Recombinant Human Granulocyte Colony-Stimulating Market Facts & Figures
8.1 China Recombinant Human Granulocyte Colony-Stimulating Sales by Company
8.1.1 China Recombinant Human Granulocyte Colony-Stimulating Sales by Company (2016-2021)
8.1.2 China Recombinant Human Granulocyte Colony-Stimulating Revenue by Company (2016-2021)
8.2 China Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Type
8.2.1 China Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Type (2016-2021)
8.2.2 China Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Type (2022-2027)
8.3 China Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Application
8.3.1 China 313 Sales Breakdown by Application (2016-2021)
8.3.2 China 313 Sales Breakdown by Application (2022-2027)
9 Japan Recombinant Human Granulocyte Colony-Stimulating Market Facts & Figures
9.1 Japan Recombinant Human Granulocyte Colony-Stimulating Sales by Company
9.1.1 Japan Recombinant Human Granulocyte Colony-Stimulating Sales by Company (2016-2021)
9.1.2 Japan Recombinant Human Granulocyte Colony-Stimulating Revenue by Company (2016-2021)
9.2 Japan Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Type
9.2.1 Japan Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Type (2016-2021)
9.2.2 Japan Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Type (2022-2027)
9.3 Japan Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Application
9.3.1 Japan Feb. Sales Breakdown by Application (2016-2021)
9.3.2 Japan Feb. Sales Breakdown by Application (2022-2027)
10 Southeast Asia Recombinant Human Granulocyte Colony-Stimulating Market Facts & Figures
10.1 Southeast Asia Recombinant Human Granulocyte Colony-Stimulating Sales by Company
10.1.1 Southeast Asia Recombinant Human Granulocyte Colony-Stimulating Sales by Company (2016-2021)
10.1.2 Southeast Asia Recombinant Human Granulocyte Colony-Stimulating Revenue by Company (2016-2021)
10.2 Southeast Asia Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Type
10.2.1 Southeast Asia Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Type (2016-2021)
10.2.2 Southeast Asia Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Type (2022-2027)
10.3 Southeast Asia Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Application
10.3.1 Southeast Asia KG Sales Breakdown by Application (2016-2021)
10.3.2 Southeast Asia KG Sales Breakdown by Application (2022-2027)
11 India Recombinant Human Granulocyte Colony-Stimulating Market Facts & Figures
11.1 India Recombinant Human Granulocyte Colony-Stimulating Sales by Company
11.1.1 India Recombinant Human Granulocyte Colony-Stimulating Sales by Company (2016-2021)
11.1.2 India Recombinant Human Granulocyte Colony-Stimulating Revenue by Company (2016-2021)
11.2 India Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Type
11.2.1 India Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Type (2016-2021)
11.2.2 India Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Type (2022-2027)
11.3 India Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Application
11.3.1 India Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Application (2016-2021)
11.3.2 India Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Application (2022-2027)
12 Company Profiles and Key Figures in Recombinant Human Granulocyte Colony-Stimulating Business
12.1 Amgen
12.1.1 Amgen Corporation Information
12.1.2 Amgen Business Overview
12.1.3 Amgen Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue and Gross Margin (2016-2021)
12.1.4 Amgen Recombinant Human Granulocyte Colony-Stimulating Products Offered
12.1.5 Amgen Recent Development
12.2 Qilu Pharmaceutical
12.2.1 Qilu Pharmaceutical Corporation Information
12.2.2 Qilu Pharmaceutical Business Overview
12.2.3 Qilu Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue and Gross Margin (2016-2021)
12.2.4 Qilu Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Products Offered
12.2.5 Qilu Pharmaceutical Recent Development
12.3 Shijiazhuang Pharmaceutical
12.3.1 Shijiazhuang Pharmaceutical Corporation Information
12.3.2 Shijiazhuang Pharmaceutical Business Overview
12.3.3 Shijiazhuang Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue and Gross Margin (2016-2021)
12.3.4 Shijiazhuang Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Products Offered
12.3.5 Shijiazhuang Pharmaceutical Recent Development
12.4 Kyowa Hakko Kirin
12.4.1 Kyowa Hakko Kirin Corporation Information
12.4.2 Kyowa Hakko Kirin Business Overview
12.4.3 Kyowa Hakko Kirin Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue and Gross Margin (2016-2021)
12.4.4 Kyowa Hakko Kirin Recombinant Human Granulocyte Colony-Stimulating Products Offered
12.4.5 Kyowa Hakko Kirin Recent Development
12.5 Gensci
12.5.1 Gensci Corporation Information
12.5.2 Gensci Business Overview
12.5.3 Gensci Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue and Gross Margin (2016-2021)
12.5.4 Gensci Recombinant Human Granulocyte Colony-Stimulating Products Offered
12.5.5 Gensci Recent Development
12.6 Amoytop Biotech
12.6.1 Amoytop Biotech Corporation Information
12.6.2 Amoytop Biotech Business Overview
12.6.3 Amoytop Biotech Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue and Gross Margin (2016-2021)
12.6.4 Amoytop Biotech Recombinant Human Granulocyte Colony-Stimulating Products Offered
12.6.5 Amoytop Biotech Recent Development
12.7 Hangzhou Jiuyuan
12.7.1 Hangzhou Jiuyuan Corporation Information
12.7.2 Hangzhou Jiuyuan Business Overview
12.7.3 Hangzhou Jiuyuan Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue and Gross Margin (2016-2021)
12.7.4 Hangzhou Jiuyuan Recombinant Human Granulocyte Colony-Stimulating Products Offered
12.7.5 Hangzhou Jiuyuan Recent Development
12.8 Huaxin
12.8.1 Huaxin Corporation Information
12.8.2 Huaxin Business Overview
12.8.3 Huaxin Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue and Gross Margin (2016-2021)
12.8.4 Huaxin Recombinant Human Granulocyte Colony-Stimulating Products Offered
12.8.5 Huaxin Recent Development
12.9 Triprime
12.9.1 Triprime Corporation Information
12.9.2 Triprime Business Overview
12.9.3 Triprime Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue and Gross Margin (2016-2021)
12.9.4 Triprime Recombinant Human Granulocyte Colony-Stimulating Products Offered
12.9.5 Triprime Recent Development
12.10 Sinovac
12.10.1 Sinovac Corporation Information
12.10.2 Sinovac Business Overview
12.10.3 Sinovac Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue and Gross Margin (2016-2021)
12.10.4 Sinovac Recombinant Human Granulocyte Colony-Stimulating Products Offered
12.10.5 Sinovac Recent Development
12.11 Zhaoke
12.11.1 Zhaoke Corporation Information
12.11.2 Zhaoke Business Overview
12.11.3 Zhaoke Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue and Gross Margin (2016-2021)
12.11.4 Zhaoke Recombinant Human Granulocyte Colony-Stimulating Products Offered
12.11.5 Zhaoke Recent Development
12.12 Kawin
12.12.1 Kawin Corporation Information
12.12.2 Kawin Business Overview
12.12.3 Kawin Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue and Gross Margin (2016-2021)
12.12.4 Kawin Recombinant Human Granulocyte Colony-Stimulating Products Offered
12.12.5 Kawin Recent Development
13 Recombinant Human Granulocyte Colony-Stimulating Manufacturing Cost Analysis
13.1 Recombinant Human Granulocyte Colony-Stimulating Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Recombinant Human Granulocyte Colony-Stimulating
13.4 Recombinant Human Granulocyte Colony-Stimulating Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Recombinant Human Granulocyte Colony-Stimulating Distributors List
14.3 Recombinant Human Granulocyte Colony-Stimulating Customers
15 Market Dynamics
15.1 Recombinant Human Granulocyte Colony-Stimulating Market Trends
15.2 Recombinant Human Granulocyte Colony-Stimulating Drivers
15.3 Recombinant Human Granulocyte Colony-Stimulating Market Challenges
15.4 Recombinant Human Granulocyte Colony-Stimulating Market Restraints
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer
1.1 Recombinant Human Granulocyte Colony-Stimulating Product Scope
1.2 Recombinant Human Granulocyte Colony-Stimulating Segment by Type
1.2.1 Global Recombinant Human Granulocyte Colony-Stimulating Sales by Type (2016 & 2021 & 2027)
1.2.2 Lenograstim (Granocyte)
1.2.3 Filgrastim (Neupogen, Zarzio, Nivestim, Ratiograstim)
1.2.4 Others
1.3 Recombinant Human Granulocyte Colony-Stimulating Segment by Application
1.3.1 Global Recombinant Human Granulocyte Colony-Stimulating Sales Comparison by Application (2016 & 2021 & 2027)
1.3.2 Chemotherapy Induced Neutropenia
1.3.3 Before Blood Donation
1.3.4 Stem Cell Transplants
1.3.5 Others
1.4 Recombinant Human Granulocyte Colony-Stimulating Market Estimates and Forecasts (2016-2027)
1.4.1 Global Recombinant Human Granulocyte Colony-Stimulating Market Size in Value Growth Rate (2016-2027)
1.4.2 Global Recombinant Human Granulocyte Colony-Stimulating Market Size in Volume Growth Rate (2016-2027)
1.4.3 Global Recombinant Human Granulocyte Colony-Stimulating Price Trends (2016-2027)
2 Recombinant Human Granulocyte Colony-Stimulating Estimates and Forecasts by Region
2.1 Global Recombinant Human Granulocyte Colony-Stimulating Market Size by Region: 2016 VS 2021 VS 2027
2.2 Global Recombinant Human Granulocyte Colony-Stimulating Retrospective Market Scenario by Region (2016-2021)
2.2.1 Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Region (2016-2021)
2.2.2 Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Region (2016-2021)
2.3 Global Recombinant Human Granulocyte Colony-Stimulating Market Estimates and Forecasts by Region (2022-2027)
2.3.1 Global Recombinant Human Granulocyte Colony-Stimulating Sales Estimates and Forecasts by Region (2022-2027)
2.3.2 Global Recombinant Human Granulocyte Colony-Stimulating Revenue Forecast by Region (2022-2027)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 North America Recombinant Human Granulocyte Colony-Stimulating Estimates and Projections (2016-2027)
2.4.2 Europe Recombinant Human Granulocyte Colony-Stimulating Estimates and Projections (2016-2027)
2.4.3 China Recombinant Human Granulocyte Colony-Stimulating Estimates and Projections (2016-2027)
2.4.4 Japan Recombinant Human Granulocyte Colony-Stimulating Estimates and Projections (2016-2027)
2.4.5 Southeast Asia Recombinant Human Granulocyte Colony-Stimulating Estimates and Projections (2016-2027)
2.4.6 India Recombinant Human Granulocyte Colony-Stimulating Estimates and Projections (2016-2027)
3 Global Recombinant Human Granulocyte Colony-Stimulating Competition Landscape by Players
3.1 Global Top Recombinant Human Granulocyte Colony-Stimulating Players by Sales (2016-2021)
3.2 Global Top Recombinant Human Granulocyte Colony-Stimulating Players by Revenue (2016-2021)
3.3 Global Recombinant Human Granulocyte Colony-Stimulating Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Recombinant Human Granulocyte Colony-Stimulating as of 2020)
3.4 Global Recombinant Human Granulocyte Colony-Stimulating Average Price by Company (2016-2021)
3.5 Manufacturers Recombinant Human Granulocyte Colony-Stimulating Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Global Recombinant Human Granulocyte Colony-Stimulating Market Size by Type
4.1 Global Recombinant Human Granulocyte Colony-Stimulating Historic Market Review by Type (2016-2021)
4.1.1 Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Type (2016-2021)
4.1.2 Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Type (2016-2021)
4.1.3 Global Recombinant Human Granulocyte Colony-Stimulating Price by Type (2016-2021)
4.2 Global Recombinant Human Granulocyte Colony-Stimulating Market Estimates and Forecasts by Type (2022-2027)
4.2.1 Global Recombinant Human Granulocyte Colony-Stimulating Sales Forecast by Type (2022-2027)
4.2.2 Global Recombinant Human Granulocyte Colony-Stimulating Revenue Forecast by Type (2022-2027)
4.2.3 Global Recombinant Human Granulocyte Colony-Stimulating Price Forecast by Type (2022-2027)
5 Global Recombinant Human Granulocyte Colony-Stimulating Market Size by Application
5.1 Global Recombinant Human Granulocyte Colony-Stimulating Historic Market Review by Application (2016-2021)
5.1.1 Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Application (2016-2021)
5.1.2 Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Application (2016-2021)
5.1.3 Global Recombinant Human Granulocyte Colony-Stimulating Price by Application (2016-2021)
5.2 Global Recombinant Human Granulocyte Colony-Stimulating Market Estimates and Forecasts by Application (2022-2027)
5.2.1 Global Recombinant Human Granulocyte Colony-Stimulating Sales Forecast by Application (2022-2027)
5.2.2 Global Recombinant Human Granulocyte Colony-Stimulating Revenue Forecast by Application (2022-2027)
5.2.3 Global Recombinant Human Granulocyte Colony-Stimulating Price Forecast by Application (2022-2027)
6 North America Recombinant Human Granulocyte Colony-Stimulating Market Facts & Figures
6.1 North America Recombinant Human Granulocyte Colony-Stimulating Sales by Company
6.1.1 North America Recombinant Human Granulocyte Colony-Stimulating Sales by Company (2016-2021)
6.1.2 North America Recombinant Human Granulocyte Colony-Stimulating Revenue by Company (2016-2021)
6.2 North America Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Type
6.2.1 North America Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Type (2016-2021)
6.2.2 North America Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Type (2022-2027)
6.3 North America Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Application
6.3.1 North America Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Application (2016-2021)
6.3.2 North America Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Application (2022-2027)
7 Europe Recombinant Human Granulocyte Colony-Stimulating Market Facts & Figures
7.1 Europe Recombinant Human Granulocyte Colony-Stimulating Sales by Company
7.1.1 Europe Recombinant Human Granulocyte Colony-Stimulating Sales by Company (2016-2021)
7.1.2 Europe Recombinant Human Granulocyte Colony-Stimulating Revenue by Company (2016-2021)
7.2 Europe Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Type
7.2.1 Europe Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Type (2016-2021)
7.2.2 Europe Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Type (2022-2027)
7.3 Europe Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Application
7.3.1 Europe 147 Sales Breakdown by Application (2016-2021)
7.3.2 Europe 147 Sales Breakdown by Application (2022-2027)
8 China Recombinant Human Granulocyte Colony-Stimulating Market Facts & Figures
8.1 China Recombinant Human Granulocyte Colony-Stimulating Sales by Company
8.1.1 China Recombinant Human Granulocyte Colony-Stimulating Sales by Company (2016-2021)
8.1.2 China Recombinant Human Granulocyte Colony-Stimulating Revenue by Company (2016-2021)
8.2 China Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Type
8.2.1 China Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Type (2016-2021)
8.2.2 China Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Type (2022-2027)
8.3 China Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Application
8.3.1 China 313 Sales Breakdown by Application (2016-2021)
8.3.2 China 313 Sales Breakdown by Application (2022-2027)
9 Japan Recombinant Human Granulocyte Colony-Stimulating Market Facts & Figures
9.1 Japan Recombinant Human Granulocyte Colony-Stimulating Sales by Company
9.1.1 Japan Recombinant Human Granulocyte Colony-Stimulating Sales by Company (2016-2021)
9.1.2 Japan Recombinant Human Granulocyte Colony-Stimulating Revenue by Company (2016-2021)
9.2 Japan Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Type
9.2.1 Japan Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Type (2016-2021)
9.2.2 Japan Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Type (2022-2027)
9.3 Japan Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Application
9.3.1 Japan Feb. Sales Breakdown by Application (2016-2021)
9.3.2 Japan Feb. Sales Breakdown by Application (2022-2027)
10 Southeast Asia Recombinant Human Granulocyte Colony-Stimulating Market Facts & Figures
10.1 Southeast Asia Recombinant Human Granulocyte Colony-Stimulating Sales by Company
10.1.1 Southeast Asia Recombinant Human Granulocyte Colony-Stimulating Sales by Company (2016-2021)
10.1.2 Southeast Asia Recombinant Human Granulocyte Colony-Stimulating Revenue by Company (2016-2021)
10.2 Southeast Asia Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Type
10.2.1 Southeast Asia Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Type (2016-2021)
10.2.2 Southeast Asia Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Type (2022-2027)
10.3 Southeast Asia Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Application
10.3.1 Southeast Asia KG Sales Breakdown by Application (2016-2021)
10.3.2 Southeast Asia KG Sales Breakdown by Application (2022-2027)
11 India Recombinant Human Granulocyte Colony-Stimulating Market Facts & Figures
11.1 India Recombinant Human Granulocyte Colony-Stimulating Sales by Company
11.1.1 India Recombinant Human Granulocyte Colony-Stimulating Sales by Company (2016-2021)
11.1.2 India Recombinant Human Granulocyte Colony-Stimulating Revenue by Company (2016-2021)
11.2 India Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Type
11.2.1 India Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Type (2016-2021)
11.2.2 India Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Type (2022-2027)
11.3 India Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Application
11.3.1 India Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Application (2016-2021)
11.3.2 India Recombinant Human Granulocyte Colony-Stimulating Sales Breakdown by Application (2022-2027)
12 Company Profiles and Key Figures in Recombinant Human Granulocyte Colony-Stimulating Business
12.1 Amgen
12.1.1 Amgen Corporation Information
12.1.2 Amgen Business Overview
12.1.3 Amgen Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue and Gross Margin (2016-2021)
12.1.4 Amgen Recombinant Human Granulocyte Colony-Stimulating Products Offered
12.1.5 Amgen Recent Development
12.2 Qilu Pharmaceutical
12.2.1 Qilu Pharmaceutical Corporation Information
12.2.2 Qilu Pharmaceutical Business Overview
12.2.3 Qilu Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue and Gross Margin (2016-2021)
12.2.4 Qilu Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Products Offered
12.2.5 Qilu Pharmaceutical Recent Development
12.3 Shijiazhuang Pharmaceutical
12.3.1 Shijiazhuang Pharmaceutical Corporation Information
12.3.2 Shijiazhuang Pharmaceutical Business Overview
12.3.3 Shijiazhuang Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue and Gross Margin (2016-2021)
12.3.4 Shijiazhuang Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Products Offered
12.3.5 Shijiazhuang Pharmaceutical Recent Development
12.4 Kyowa Hakko Kirin
12.4.1 Kyowa Hakko Kirin Corporation Information
12.4.2 Kyowa Hakko Kirin Business Overview
12.4.3 Kyowa Hakko Kirin Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue and Gross Margin (2016-2021)
12.4.4 Kyowa Hakko Kirin Recombinant Human Granulocyte Colony-Stimulating Products Offered
12.4.5 Kyowa Hakko Kirin Recent Development
12.5 Gensci
12.5.1 Gensci Corporation Information
12.5.2 Gensci Business Overview
12.5.3 Gensci Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue and Gross Margin (2016-2021)
12.5.4 Gensci Recombinant Human Granulocyte Colony-Stimulating Products Offered
12.5.5 Gensci Recent Development
12.6 Amoytop Biotech
12.6.1 Amoytop Biotech Corporation Information
12.6.2 Amoytop Biotech Business Overview
12.6.3 Amoytop Biotech Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue and Gross Margin (2016-2021)
12.6.4 Amoytop Biotech Recombinant Human Granulocyte Colony-Stimulating Products Offered
12.6.5 Amoytop Biotech Recent Development
12.7 Hangzhou Jiuyuan
12.7.1 Hangzhou Jiuyuan Corporation Information
12.7.2 Hangzhou Jiuyuan Business Overview
12.7.3 Hangzhou Jiuyuan Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue and Gross Margin (2016-2021)
12.7.4 Hangzhou Jiuyuan Recombinant Human Granulocyte Colony-Stimulating Products Offered
12.7.5 Hangzhou Jiuyuan Recent Development
12.8 Huaxin
12.8.1 Huaxin Corporation Information
12.8.2 Huaxin Business Overview
12.8.3 Huaxin Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue and Gross Margin (2016-2021)
12.8.4 Huaxin Recombinant Human Granulocyte Colony-Stimulating Products Offered
12.8.5 Huaxin Recent Development
12.9 Triprime
12.9.1 Triprime Corporation Information
12.9.2 Triprime Business Overview
12.9.3 Triprime Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue and Gross Margin (2016-2021)
12.9.4 Triprime Recombinant Human Granulocyte Colony-Stimulating Products Offered
12.9.5 Triprime Recent Development
12.10 Sinovac
12.10.1 Sinovac Corporation Information
12.10.2 Sinovac Business Overview
12.10.3 Sinovac Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue and Gross Margin (2016-2021)
12.10.4 Sinovac Recombinant Human Granulocyte Colony-Stimulating Products Offered
12.10.5 Sinovac Recent Development
12.11 Zhaoke
12.11.1 Zhaoke Corporation Information
12.11.2 Zhaoke Business Overview
12.11.3 Zhaoke Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue and Gross Margin (2016-2021)
12.11.4 Zhaoke Recombinant Human Granulocyte Colony-Stimulating Products Offered
12.11.5 Zhaoke Recent Development
12.12 Kawin
12.12.1 Kawin Corporation Information
12.12.2 Kawin Business Overview
12.12.3 Kawin Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue and Gross Margin (2016-2021)
12.12.4 Kawin Recombinant Human Granulocyte Colony-Stimulating Products Offered
12.12.5 Kawin Recent Development
13 Recombinant Human Granulocyte Colony-Stimulating Manufacturing Cost Analysis
13.1 Recombinant Human Granulocyte Colony-Stimulating Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Recombinant Human Granulocyte Colony-Stimulating
13.4 Recombinant Human Granulocyte Colony-Stimulating Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Recombinant Human Granulocyte Colony-Stimulating Distributors List
14.3 Recombinant Human Granulocyte Colony-Stimulating Customers
15 Market Dynamics
15.1 Recombinant Human Granulocyte Colony-Stimulating Market Trends
15.2 Recombinant Human Granulocyte Colony-Stimulating Drivers
15.3 Recombinant Human Granulocyte Colony-Stimulating Market Challenges
15.4 Recombinant Human Granulocyte Colony-Stimulating Market Restraints
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer
